Facts of Rydapt (Midostaurin Capsules)
Product: RYDAPT® (midostaurin) capsules, for oral use
Indication: blood cell cancer (acute myeloid leukemia-AML, mast cell leukemia-MCL)
Strength: Capsules: 25 mg
Company: Novartis Pharmaceuticals Corporation
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Rydapt (Midostaurin ) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Rydapt (Midostaurin) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Rydapt is?
RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with:
• Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Limitations of Use:
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
• Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
What Midostaurin is?
Midostaurin, sold under the brand name Rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.